Trial Profile
A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel (Oral Paclitaxel) Compared to Taxol (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMAL; OPTIMAL 3
- Sponsors Daehwa Pharmaceutical
- 26 Dec 2023 Planned End Date changed from 31 Mar 2022 to 31 Mar 2024.
- 26 Dec 2023 Planned primary completion date changed from 31 Dec 2020 to 30 Jan 2024.
- 26 Dec 2023 Status changed from recruiting to active, no longer recruiting.